Skip to Content
Merck

C1493

Cilnidipine

≥98% (HPLC), powder

Synonym(s):

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester, FRC 8653

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C27H28N2O7
CAS Number:
132203-70-4
Molecular Weight:
492.52
NACRES:
NA.77
PubChem Substance ID:
24892414
UNSPSC Code:
12352200
MDL number:
MFCD00865853

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Cilnidipine, ≥98% (HPLC), powder

InChI key

KJEBULYHNRNJTE-DHZHZOJOSA-N

SMILES string

COCCOC(=O)C1=C(C)NC(C)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC\C=C\c3ccccc3

InChI

1S/C27H28N2O7/c1-18-23(26(30)35-14-8-11-20-9-5-4-6-10-20)25(21-12-7-13-22(17-21)29(32)33)24(19(2)28-18)27(31)36-16-15-34-3/h4-13,17,25,28H,14-16H2,1-3H3/b11-8+

assay

≥98% (HPLC)

form

powder

storage condition

protect from light

color

light yellow

solubility

H2O: ≤2 mg/mL
DMSO: ≥20 mg/mL

Quality Level

100

Related Categories

Application

Cilnidipine has been used:
  • in cell viability assay of pheochromocytoma (nPC12) cells
  • in photoirradiation and photodegradation studies
  • to understand effect on albuminuria in diabetic nephropathy

Biochem/physiol Actions

A slow-acting Ca2+ channel blocker, antihypertensive; vasodilator.
Cilnidipine is a slow-acting Ca2+ channel blocker; antihypertensive; vasodilator; dual blocker of L-type voltage-gated Ca2+ channels in vascular smooth muscle and N-type Ca2+ channels in sympathetic nerve terminals that supply blood vessels. Cilnidipine may offer an advantage over nifedipine as the long term intake of the latter has been linked to increased risk of myocardial infarction and mortality in patients with coronary artery disease. Cilnidipine lowers blood pressure, but has less effect on sympathetic activity. Unlike nifedipine, cilnidipine does not inhibit PKC.

Features and Benefits

This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

Protect from high temperatures.

pictograms

Corrosion
GHS05

signalword

Danger

hcodes

H318

Hazard Classifications

Eye Dam. 1

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000521145
0000521147
0000521147
0000521145
0000518100

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sayaka Masada et al.
Scientific reports, 9(1), 11852-11852 (2019-08-16)
In July 2018, certain valsartan-containing drugs were voluntary recalled in Japan owing to contamination with N-nitrosodimethylamine (NDMA), a probable human carcinogen. In this study, an HPLC method was developed for the quantitative detection of NDMA simultaneously eluted with valsartan. Good
Cilnidipine mediates a neuroprotective effect by scavenging free radicals and activating the phosphatidylinositol 3-kinase pathway
Lee YJ, et al.
Journal of Neurochemistry, 111(1), 90-100 (2009)
Kazuomi Kario et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(2), 133-142 (2013-01-24)
The Ambulatory Blood Pressure Control and Home Blood Pressure (Morning and Evening) Lowering By N-Channel Blocker Cilnidipine (ACHIEVE-ONE) trial is a large-scale clinical study on blood pressure (BP) and pulse rate (PR) in the real world with use of cilnidipine
Photoinduced Aromatization of Asymmetrically Substituted 1, 4-Dihydropyridine Derivative Drug Cilnidipine
Ahmad W
Journal of Photochemistry, 2014(1), 90-100 (2014)
Hiroaki Matsuoka et al.
Clinical and experimental hypertension (New York, N.Y. : 1993), 33(7), 455-462 (2011-06-09)
Recently, it has been demonstrated that L-/N-type calcium channel blockers (CCBs), cilnidipine, but not L-type CCB, decreased urinary protein in renin-angiotensin system (RAS), inhibitor-treated hypertensive patients with macroproteinuria. However, the antiproteinuric effect of cilnidipine was weaker in diabetic patients than
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service